| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-08 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-08 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-08 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-07 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.18 | 3e-07 |